Author & Research Contributor
Published in 2026 | VOLUME 03, JULY ISSUE 07The treatment of insulin-dependent type 2 diabetes mellitus (T2DM) is often complicated by the psychological and logistical challenges inherent to daily subcutaneous injections. The introduction of Awiqli® (insulin icodec-abae)—a first-in-class basal insulin analog administered once weekly—offers a practical alternative. By modifying the molecular core of human insulin through the addition of a C20 icosanoic diacid side chain, insulin icodec achieves an extended half-life of approximately 196 hours via reversible binding to serum albumin. Data from the global Phase 3a clinical trial program demonstrate that weekly insulin icodec provides non-inferior—and, in several studies, superior—glycemic control (assessed by reductions in HbA1c levels and time in target range) compared to established daily basal insulins, such as insulin glargine U100 and insulin degludec. However, its ultra-long-acting pharmacokinetic profile necessitates careful clinical attention, particularly regarding the transient risk of hypoglycemia at the start of the weekly cycle and the rigidity of titration regimens. This review examines the structural pharmacology, key clinical trial data, and practical implementation strategies required to safely utilize this novel ultra-long-acting insulin in routine clinical practice.
.